qHTS to Identify Inhibitors of the Arf GTPase-activating Protein ASAP1

qHTS 鉴定 Arf GTP 酶激活蛋白 ASAP1 的抑制剂

• 批准号: 9359872
• 负责人: Matthew Hall
• 金额: $ 12.2万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9359872
• 关键词: Adaptor Signaling Protein; Antineoplastic Agents; Biological Assay; Biology; Chemicals; Collaborations; Colorectal Cancer; Communities; Development; Disease; Extramural Activities; Fostering; GTPase-Activating Proteins; General Population; Genomics; Goals; Human; Informatics; Lead; Link; Modeling; Pharmaceutical Chemistry; Pharmaceutical Preparations; Process; Publications; Research; Research Personnel; Resources; Synthesis Chemistry; United States National Institutes of Health; Validation; Work; assay development; base; drug development; drug discovery; high throughput screening; human disease; improved; inhibitor/antagonist; new technology; novel; novel therapeutics; screening; small molecule; small molecule inhibitor; small molecule therapeutics; therapeutic development; tool; tumor; tumor progression

During this period, the NCGC has worked to adapt and optimize an HTS-amenable ASAP1 assay to enable high-throughput screening. As a center, the NCGC has fostered and maintained over 110 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.

在此期间，NCGC一直致力于适应和优化HTS无效的ASAP1分析，以实现高通量筛选。 作为一个中心，NCGC与NIH和壁外研究人员培养并维持了110多次积极合作，从而促进了整个人类疾病范围内的药物发现工作。 这些努力导致了数十个高通量屏幕和许多药物化学运动，以进一步改善筛选效果，为我们的合作者和一般研究社区提供出版物以及各种有希望的小分子探测器和铅。 此外，NCGC努力促进许多信息计划，以更好地利用现有的药物和疾病目标信息，并为公众提供易于获得的资源，从而进一步促进针对人类疾病的新疗法的发展。